The challenges of treating C-diff prior to tre... - CLL Support

CLL Support

23,339 members40,047 posts

The challenges of treating C-diff prior to treating CLL

katier profile image
1 Reply

In response to other messages I've read for those of us with CLL/SLL; My CLL (previously 'dormant') flared up along with the discovery of C-diff and lymphoma...(Not a fun holiday season for me, either). WE learned that Flagyl doesn't work given our compromised immune systems and that most Insurance Companies won't pay for the one drug that WILL work, Vancomycn. 'Vanco' started in the hospital showed early signs of working BUT your Doc's Rx for Vancomycn CAPSULES costs $3,000! and your insurance company won't pay for it. You can go BACK into the Hospital and have your Dr. prescribe Vanco, in the LIQUID form normally used as an IV, mixed up by the Hospital Pharmacy costing you about $50 for a 14 day supply! Anyone who's suffered with C-diff, knows you can't let this go on forever. When the C-diff is 'cured' you can begin talking about Chemotherapy for your CLL/SLL with your oncologist.

(Post title edited to reflect post content - Admin)

Written by
katier profile image
katier
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Cllcanada profile image
CllcanadaTop Poster CURE Hero

Why not try fecal pills or perhaps a fecal transplant.... very high cure rate for chronic C.diff...

medscape.com/viewarticle/81...

Not what you're looking for?

You may also like...

"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies

Encouraging news in this abstract from CLL/SLL researchers at the Northwestern Memorial Hospital,...
AussieNeil profile image
Partner

Aussies, please consider enrolling in this study into the personal impact of CLL and help our world wide CLL/SLL community

Australians diagnosed with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL),...
AussieNeil profile image
Partner

BTK Degrader Shows Potential for Treating Refractory CLL and SLL

A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients...
Jm954 profile image
Administrator

White Paper recommends steps to improve the care and support of people with Chronic Lymphocytic Leukemia who face immune challenges

". . . despite advances in therapy, infection remains a major risk in CLL and is a key challenge...
CLLerinOz profile image
Administrator